...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Resverlogix Invites Collaborations for use of Apabetalone in Trials and Studies to Combat the Spread of COVID-19 Based on New Research

Re: Recent findings point to BET protein and ACE2 inhibition as possible means to slow and reduce the impact of COVID-19....

posted on Mar 23, 2020 09:42AM

Two unexpected developments!

The apparent withdrawal from the NFK could be because (a) the organizers have decided the data to be presented were too similar to the AHA (but if so they should have spotted that earlier), (b) RVX realised they had made an error in some important statistics they were planning to present, (c) an imminent BP buyer does not want it presented for some reason. I don't think it could be anything to do with the presenter. If he is indisposed for some reason another author would stand in.

The announcement about covid-19 is confusing too. As one of us has already pointed out, it would make more sense to go directly to the clinical trial investigators. Perhaps they tried and made no progress...

 

 

Share
New Message
Please login to post a reply